羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600285 羚锐制药

已收盘 11-22 15:00:00

{"stockData":{"symbol":"600285","market":"SH","secType":"STK","nameCN":"羚锐制药","latestPrice":20.81,"timestamp":1732258800000,"preClose":21.56,"halted":0,"volume":7113730,"delay":0,"floatShares":567000000,"shares":567000000,"eps":1.1917,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.75,"latestTime":"11-22 15:00:00","open":21.5,"high":21.6,"low":20.79,"amount":150000000,"amplitude":0.0376,"askPrice":20.81,"askSize":372,"bidPrice":20.8,"bidSize":248,"shortable":0,"etf":0,"ttmEps":1.1917,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":21.56,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":23.72,"lowLimit":19.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":567115486,"pbRate":4.08,"roa":"--","roe":"20.44%","epsLYR":1.012,"committee":0.030986,"marketValue":11802000000,"floatMarketCap":11802000000,"peRate":17.462449,"changeRate":-0.0348,"turnoverRate":0.0125,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。"},"requestUrl":"/m/hq/s/600285","defaultTab":"news","newsList":[{"id":"2485284194","title":"羚锐制药11月22日遭主力抛售327万元 环比增加541.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485284194","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485284194?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:18","pubTimestamp":1732259911,"startTime":"0","endTime":"0","summary":"11月22日, 羚锐制药股价跌3.48%，报收20.81元，成交金额1.50亿元，换手率1.25%，振幅3.76%，量比0.95。羚锐制药今日主力资金净流出327万元，上一交易日主力净流出51万元，今日环比增加541.18%。该股近5个交易日下跌3.48%，主力资金累计净流出2111万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出9597万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122152329abd6b3b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122152329abd6b3b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","BK0070","BK0077","600285"],"gpt_icon":0},{"id":"2484099310","title":"羚锐制药11月19日主力资金流出529万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2484099310","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484099310?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:21","pubTimestamp":1732000883,"startTime":"0","endTime":"0","summary":"11月19日, 羚锐制药股价涨1.62%，报收21.34元，成交金额1.50亿元，换手率1.25%，振幅2.43%，量比0.70。羚锐制药今日主力资金净流出529万元，连续3日净流出，上一交易日主力净流出1431万元，今日环比减少63.03%。该股近5个交易日下跌6.07%，主力资金累计净流出1936万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2.16亿元，其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119153812a2450c7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119153812a2450c7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0077","600285","BK0239","BK0070"],"gpt_icon":0},{"id":"2484611880","title":"羚锐制药11月18日遭主力抛售1431万元 环比增加134.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484611880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484611880?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:18","pubTimestamp":1731914337,"startTime":"0","endTime":"0","summary":"11月18日, 羚锐制药股价跌2.60%，报收21.00元，成交金额2.47亿元，换手率2.05%，振幅4.13%，量比1.15。羚锐制药今日主力资金净流出1431万元，上一交易日主力净流出610万元，今日环比增加134.59%。该股近5个交易日下跌8.70%，主力资金累计净流出3833万元；近20日主力资金累计净流出1.99亿元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152651a2422043&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118152651a2422043&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","BK0070","600285","BK0077"],"gpt_icon":0},{"id":"2483649523","title":"羚锐制药：第三季度营业收入8.53亿元，同比增长5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483649523","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483649523?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:30","pubTimestamp":1731634200,"startTime":"0","endTime":"0","summary":"来源：Gangtise投研\n羚锐制药 2024年第三季度营业收入8.53亿元，同比增长5.83%，归属于上市公司股东的净利润1.61亿元，同比增长7.80%。年初至报告期末，公司营业收入27.59亿元，同比增长10.07%，净利润5.74亿元，同比增长23.10%。经营活动产生的现金流量净额3.50亿元，同比下降31.19%，主要系销售商品收到的资金减少及支付其他经营活动的现金增加所致。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-11-15/doc-incwcefn9665016.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-11-15/doc-incwcefn9665016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600285"],"gpt_icon":0},{"id":"2482273829","title":"羚锐制药11月11日获主力加仓2333万元 环比增加478.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482273829","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482273829?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:19","pubTimestamp":1731309545,"startTime":"0","endTime":"0","summary":"11月11日, 羚锐制药股价涨0.57%，报收23.00元，成交金额2.62亿元，换手率2.03%，振幅3.28%，量比0.84。羚锐制药今日主力资金净流入2333万元，上一交易日主力净流入403万元，今日环比增加478.91%。该行业中净流入前三个股分别为众生药业、吉林敖东、羚锐制药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152359a22bb167&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152359a22bb167&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","BK0070","BK0239","BK0188","BK0077"],"gpt_icon":0},{"id":"2481900423","title":"中原证券：给予羚锐制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481900423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481900423?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:45","pubTimestamp":1730987122,"startTime":"0","endTime":"0","summary":"中原证券股份有限公司李琳琳近期对羚锐制药进行研究并发布了研究报告《季报点评：业绩增长符合预期》，本报告对羚锐制药给出买入评级，当前股价为22.6元。最新盈利预测明细如下：该股最近90天内共有12家机构给出评级，买入评级11家，增持评级1家；过去90天内机构目标均价为30.75。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700035664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","601375"],"gpt_icon":0},{"id":"2481867088","title":"羚锐制药：业绩说明会定于11月25日举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2481867088","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481867088?lang=zh_cn&edition=full","pubTime":"2024-11-06 19:48","pubTimestamp":1730893711,"startTime":"0","endTime":"0","summary":"每经AI快讯，羚锐制药 11月6日晚间发布公告称，公司2024年第三季度业绩说明会定于2024年11月25日下午16:00-17:00，以上证路演中心网络互动的形式进行。出席本次业绩说明会的人员有：董事长、总经理熊伟，董事会秘书冯国鑫，财务总监余鹏，独立董事杨钧。2023年1至12月份，羚锐制药的营业收入构成为：工业制造占比99.63%，其他行业占比0.25%。羚锐制药的董事长、总经理均是熊伟，男，40岁，学历背景为硕士。截至发稿，羚锐制药市值为122亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106194917a21cc2f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106194917a21cc2f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0077","600285","BK0188","BK0239"],"gpt_icon":0},{"id":"2481629152","title":"羚锐制药最新公告：获得莫匹罗星软膏药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481629152","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481629152?lang=zh_cn&edition=full","pubTime":"2024-11-06 16:43","pubTimestamp":1730882589,"startTime":"0","endTime":"0","summary":"羚锐制药公告，公司近日收到国家药监局核准签发的莫匹罗星软膏《药品注册证书》。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600027700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0070","600285","BK0239"],"gpt_icon":0},{"id":"2481628798","title":"羚锐制药获得莫匹罗星软膏药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481628798","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481628798?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:59","pubTimestamp":1730879948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，羚锐制药 发布公告，公司于近日收到国家药品监督管理局核准签发的莫匹罗星软膏《药品注册证书》。本次公司取得莫匹罗星软膏《药品注册证书》，进一步丰富了公司产品线，有利于提高产品市场竞争力。根据国家相关政策，此次莫匹罗星软膏按化学药品4类批准生产，可视同通过一致性评价，预计将对公司的经营产生积极影响。莫匹罗星软膏为《国家医保目录》乙类产品、《国家基本药物目录》产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106160110a21bd982&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106160110a21bd982&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0077","BK0070","600285","BK0239"],"gpt_icon":0},{"id":"2481625852","title":"羚锐制药(600285.SH)获得莫匹罗星软膏药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481625852","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481625852?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:59","pubTimestamp":1730879948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，羚锐制药 发布公告，公司于近日收到国家药品监督管理局核准签发的莫匹罗星软膏《药品注册证书》。本次公司取得莫匹罗星软膏《药品注册证书》，进一步丰富了公司产品线，有利于提高产品市场竞争力。根据国家相关政策，此次莫匹罗星软膏按化学药品4类批准生产，可视同通过一致性评价，预计将对公司的经营产生积极影响。莫匹罗星软膏为《国家医保目录》乙类产品、《国家基本药物目录》产品。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0188","600285","BK0077","BK0070"],"gpt_icon":0},{"id":"2481512337","title":"华福证券：给予羚锐制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481512337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481512337?lang=zh_cn&edition=full","pubTime":"2024-11-05 12:56","pubTimestamp":1730782575,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司陈铁林近期对羚锐制药进行研究并发布了研究报告《业绩增长稳健，持续受益于老龄化趋势》，本报告对羚锐制药给出买入评级，当前股价为21.67元。最新盈利预测明细如下：该股最近90天内共有12家机构给出评级，买入评级11家，增持评级1家；过去90天内机构目标均价为30.75。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500018141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","161027"],"gpt_icon":0},{"id":"2481598210","title":"羚锐制药（600285）11月4日主力资金净卖出490.51万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481598210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481598210?lang=zh_cn&edition=full","pubTime":"2024-11-05 08:27","pubTimestamp":1730766449,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月4日收盘，羚锐制药报收于21.45元，下跌0.56%，换手率1.93%，成交量10.93万手，成交额2.34亿元。近5日资金流向一览见下表：羚锐制药融资融券信息显示，融资方面，当日融资买入1388.08万元，融资偿还1088.91万元，融资净买入299.18万元。羚锐制药主营业务：药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500007192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","600285","BK0188","BK0077","BK0239"],"gpt_icon":0},{"id":"2481172425","title":"羚锐制药：业绩增长稳健 持续受益于老龄化趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2481172425","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481172425?lang=zh_cn&edition=full","pubTime":"2024-11-05 00:00","pubTimestamp":1730736000,"startTime":"0","endTime":"0","summary":"2024Q3：实现收入8.5 亿元，同比增长5.8%，归母净利润为1.6亿元，同比增长7.8%，扣非归母净利润1.5 亿元，同比增长4.8%。国内知名中药贴膏品牌，多剂型产品布局，共推公司长期发展。近年来，公司持续增加研发投入，注重研究化学贴片、骨科、心脑血管等领域，致力于推进已上市产品的二次开发。风险提示行业竞争加剧风险、新产品研发进度不及预期、原材料价格大幅波动风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110513262295bdcefb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110513262295bdcefb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","BK0188","BK0239","BK0070","600285"],"gpt_icon":0},{"id":"2479233242","title":"羚锐制药10月30日遭主力抛售6200万元 环比增加904.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479233242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479233242?lang=zh_cn&edition=full","pubTime":"2024-10-30 15:18","pubTimestamp":1730272708,"startTime":"0","endTime":"0","summary":"10月30日, 羚锐制药股价跌8.38%，报收21.76元，成交金额6.30亿元，换手率5.08%，振幅5.05%，量比2.93。羚锐制药今日主力资金净流出6200万元，连续6日净流出，上一交易日主力净流出617万元，今日环比增加904.86%。净流出前三个股分别为羚锐制药、达仁堂、葵花药业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030152831ab821ca9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030152831ab821ca9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","BK0070","600285","BK0077"],"gpt_icon":0},{"id":"2479294352","title":"羚锐制药大跌5.68% 2家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2479294352","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479294352?lang=zh_cn&edition=full","pubTime":"2024-10-30 09:30","pubTimestamp":1730251801,"startTime":"0","endTime":"0","summary":"10月30日，羚锐制药股价大幅下跌，截至09点30分，羚锐制药下跌5.68%，报22.40元/股，创近1个月新低，成交809万元，换手率0.06%，振幅0.42%。资金动向截止发稿，羚锐制药获得主力净流出1445万元，其中超大单流出1868万元，大单流入423万元。主营业务及业绩羚锐制药公司主营业务为药品的生产与销售。最新财报显示，今年三季报，羚锐制药实现营业收入27.59亿元，同比增长10.07%，净利润为5.74亿元，同比增长23.10%，基本每股收益为1.02元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030093231ab8072fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030093231ab8072fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0070","BK0239","BK0077","600285"],"gpt_icon":0},{"id":"2479239235","title":"羚锐制药公布三季报 前三季净利增加23.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479239235","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479239235?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:00","pubTimestamp":1730221200,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　10月30日消息，羚锐制药发布三季度报告。　　公告显示，公司前三季度营业收入2,759,116,202.14元，同比增加10.07%，归属上市公司股东的净利润573,873,093.86元，同比增加23.1%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-10-30/doc-incufzcp8414805.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-30/doc-incufzcp8414805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600285","BK0239","BK0070","BK0188","BK0077"],"gpt_icon":0},{"id":"2479458472","title":"羚锐制药：业绩符合预期 稳增长且高分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2479458472","media":"浙商证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479458472?lang=zh_cn&edition=full","pubTime":"2024-10-30 00:00","pubTimestamp":1730217600,"startTime":"0","endTime":"0","summary":"投资要点事件：羚锐制药发布2024 年三季报，报告期内实现营收27.59 亿元，归母净利润5.74 亿元，扣非归母净利润5.41 亿元；单Q3 实现营收8.53 亿元，归母净利润1.61 亿元，扣非归母净利润1.47 亿元；前三季度业绩符合预期。药店进货意愿低，促销活动难开展或为公司业绩呈现季度承压的主要原因。稀缺的稳增长且高分红标的。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103013264195bd8a49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103013264195bd8a49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","BK0070","600285","BK0188","BK0239"],"gpt_icon":0},{"id":"2479204714","title":"图解羚锐制药三季报：第三季度单季净利润同比增7.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479204714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479204714?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:22","pubTimestamp":1730193763,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药2024年三季报显示，公司主营收入27.59亿元，同比上升10.07%；归母净利润5.74亿元，同比上升23.1%；扣非净利润5.41亿元，同比上升22.54%；其中2024年第三季度，公司单季度主营收入8.53亿元，同比上升5.83%；单季度归母净利润1.61亿元，同比上升7.8%；单季度扣非净利润1.47亿元，同比上升4.81%；负债率40.61%，投资收益2954.25万元，财务费用-1319.39万元，毛利率75.0%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900031927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"gpt_icon":0},{"id":"2479642787","title":"羚锐制药(600285)9月30日股东户数3.09万户，较上期增加5.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479642787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479642787?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:01","pubTimestamp":1730192519,"startTime":"0","endTime":"0","summary":"证券之星消息，近日羚锐制药披露，截至2024年9月30日公司股东户数为3.09万户，较6月30日增加1621.0户，增幅为5.53%。在中药行业个股中，羚锐制药股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为4.96万户。从股价来看，2024年6月30日至2024年9月30日，羚锐制药区间涨幅为2.35%，在此期间股东户数增加1621.0户，增幅为5.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900029881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0070","600285","BK0077"],"gpt_icon":0},{"id":"2479424553","title":"羚锐制药(600285.SH)发前三季业绩，净利润5.74亿元，同比增长23.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479424553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479424553?lang=zh_cn&edition=full","pubTime":"2024-10-29 16:37","pubTimestamp":1730191028,"startTime":"0","endTime":"0","summary":"智通财经APP讯，羚锐制药(600285.SH)发布2024年前三季度报告，报告期内公司实现营业收入27.59亿元，同比增长10.07%;归属于上市公司股东的净利润5.74亿元，同比增长23.10%;归属于上市公司股东扣除非经常性损益净利润5.41亿元，同比增长22.54%;基本每股收益1.024元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600285"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"河南省信阳市新县将军路666号","stockEarnings":[{"period":"1week","weight":-0.0348},{"period":"1month","weight":-0.1636},{"period":"3month","weight":-0.1443},{"period":"6month","weight":-0.1327},{"period":"1year","weight":0.2573},{"period":"ytd","weight":0.2566}],"companyName":"河南羚锐制药股份有限公司","boardCode":"AI0027","perCapita":"18338股","boardName":"医药制造业","registeredCapital":"56711万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":"　　河南羚锐制药股份有限公司的主营业务为中成药制剂、化药制剂的研发、生产和销售。公司主要产品包括通络祛痛膏、壮骨麝香止痛膏、丹鹿通督片、培元通脑胶囊、参芪降糖胶囊、糠酸莫米松乳膏、小儿退热贴、咳宁胶囊、锐枢安芬太尼透皮贴剂等。公司先后获评“全国中药工业50强企业”“全国中药系统先进集体”“国家技术创新示范企业”等荣誉称号。","serverTime":1732360940989,"listedPrice":8.3,"stockholders":"30925人(较上一季度增加5.53%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"羚锐制药,600285,羚锐制药股票,羚锐制药股票老虎,羚锐制药股票老虎国际,羚锐制药行情,羚锐制药股票行情,羚锐制药股价,羚锐制药股市,羚锐制药股票价格,羚锐制药股票交易,羚锐制药股票购买,羚锐制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}